Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
Open Access
- 15 September 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (9) , e12711
Abstract
The effects on cell signalling networks upon blockade of cytotoxic T lymphocyte-associated antigen-4 (CTLA4) using the monoclonal antibody tremelimumab were studied in peripheral blood mononuclear cell (PBMC) samples from patients with metastatic melanoma. Findings Intracellular flow cytometry was used to detect phosphorylated (p) signaling molecules downstream of the T cell receptor (TCR) and cytokine receptors. PBMC from tremelimumab-treated patients were characterized by increase in pp38, pSTAT1 and pSTAT3, and decrease in pLck, pERK1/2 and pSTAT5 levels. These changes were noted in CD4 and CD8 T lymphocytes but also in CD14 monocytes. A divergent pattern of phosphorylation of Zap70, LAT, Akt and STAT6 was noted in patients with or without an objective tumor response. The administration of the CTLA4-blocking antibody tremelimumab to patients with metastatic melanoma influences signaling networks downstream of the TCR and cytokine receptors both in T cells and monocytes. The strong modulation of signaling networks in monocytes suggests that this cell subset may be involved in clinical responses to CTLA4 blockade. clinicaltrials.gov; Registration numbers NCT00090896 and NCT00471887Keywords
This publication has 46 references indexed in Scilit:
- CTLA4 blockade increases Th17 cells in patients with metastatic melanomaJournal of Translational Medicine, 2009
- Anti-CTLA-4 therapy results in higher CD4 + ICOS hi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissuesProceedings of the National Academy of Sciences, 2009
- CTLA-4 Activation of Phosphatidylinositol 3-Kinase (PI 3-K) and Protein Kinase B (PKB/AKT) Sustains T-Cell Anergy without Cell DeathPLOS ONE, 2008
- CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patientsProceedings of the National Academy of Sciences, 2008
- Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanomaJournal of Translational Medicine, 2008
- Allelic variant inCTLA4alters T cell phosphorylation patternsProceedings of the National Academy of Sciences, 2007
- Down-Regulation of the Interferon Signaling Pathway in T Lymphocytes from Patients with Metastatic MelanomaPLOS Medicine, 2007
- Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profilingNature Methods, 2006
- Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune diseaseNature, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000